These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

826 related articles for article (PubMed ID: 26577449)

  • 1. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and/or triple negative breast cancer.
    Francies FZ; Wainstein T; De Leeneer K; Cairns A; Murdoch M; Nietz S; Cubasch H; Poppe B; Van Maerken T; Crombez B; Coene I; Kerr R; Slabbert JP; Vral A; Krause A; Baeyens A; Claes KB
    BMC Cancer; 2015 Nov; 15():912. PubMed ID: 26577449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline testing of
    Woodward ER; Lalloo F; Forde C; Pugh S; Burghel GJ; Schlecht H; Harkness EF; Howell A; Howell SJ; Gandhi A; Evans DG
    J Med Genet; 2024 Mar; 61(4):385-391. PubMed ID: 38123987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing.
    Zhou J; Wang H; Fu F; Li Z; Feng Q; Wu W; Liu Y; Wang C; Chen Y
    Cancer; 2020 Jul; 126(14):3202-3208. PubMed ID: 32339256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contralateral Breast Cancer Risk Among Carriers of Germline Pathogenic Variants in
    Yadav S; Boddicker NJ; Na J; Polley EC; Hu C; Hart SN; Gnanaolivu RD; Larson N; Holtegaard S; Huang H; Dunn CA; Teras LR; Patel AV; Lacey JV; Neuhausen SL; Martinez E; Haiman C; Chen F; Ruddy KJ; Olson JE; John EM; Kurian AW; Sandler DP; O'Brien KM; Taylor JA; Weinberg CR; Anton-Culver H; Ziogas A; Zirpoli G; Goldgar DE; Palmer JR; Domchek SM; Weitzel JN; Nathanson KL; Kraft P; Couch FJ
    J Clin Oncol; 2023 Mar; 41(9):1703-1713. PubMed ID: 36623243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of mutations in BRCA genes and other candidate genes in high-risk probands or probands with breast or ovarian cancer in the Czech Republic.
    Riedlova P; Janoutova J; Hermanova B
    Mol Biol Rep; 2020 Apr; 47(4):2763-2769. PubMed ID: 32180084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
    Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR
    Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline mutations of multiple breast cancer-related genes are differentially associated with triple-negative breast cancers and prognostic factors.
    Hata C; Nakaoka H; Xiang Y; Wang D; Yang A; Liu D; Liu F; Zou Q; Wei L; Zheng K; Inoue I; You H
    J Hum Genet; 2020 Jul; 65(7):577-587. PubMed ID: 32029870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families.
    Pylkäs K; Erkko H; Nikkilä J; Sólyom S; Winqvist R
    BMC Cancer; 2008 May; 8():146. PubMed ID: 18501021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
    Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
    Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
    Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
    Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of pathogenic variants in BRCA1 and BRCA2 genes using next-generation sequencing in women with triple negative breast cancer from South India.
    Rajagopal T; Seshachalam A; Jothi A; Rathnam KK; Talluri S; Venkatabalasubranian S; Dunna NR
    Mol Biol Rep; 2022 Apr; 49(4):3025-3032. PubMed ID: 35020120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low prevalence of germline PALB2 mutations in Australian triple-negative breast cancer.
    Wong-Brown MW; Avery-Kiejda KA; Bowden NA; Scott RJ
    Int J Cancer; 2014 Jan; 134(2):301-5. PubMed ID: 23824750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PALB2 mutations in BRCA1/2-mutation negative breast and ovarian cancer patients from Poland.
    Kluska A; Balabas A; Piatkowska M; Czarny K; Paczkowska K; Nowakowska D; Mikula M; Ostrowski J
    BMC Med Genomics; 2017 Mar; 10(1):14. PubMed ID: 28279176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of PALB2 gene in BRCA1/BRCA2 negative Spanish hereditary breast/ovarian cancer families with pancreatic cancer cases.
    Blanco A; de la Hoya M; Osorio A; Diez O; Miramar MD; Infante M; Martinez-Bouzas C; Torres A; Lasa A; Llort G; Brunet J; Graña B; Perez Segura P; Garcia MJ; Gutiérrez-Enríquez S; Carracedo Á; Tejada MI; Velasco EA; Calvo MT; Balmaña J; Benitez J; Caldés T; Vega A
    PLoS One; 2013; 8(7):e67538. PubMed ID: 23935836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
    Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
    Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutations predisposing to breast cancer in 12 candidate genes in breast cancer patients from Poland.
    Cybulski C; Lubiński J; Wokołorczyk D; Kuźniak W; Kashyap A; Sopik V; Huzarski T; Gronwald J; Byrski T; Szwiec M; Jakubowska A; Górski B; Dębniak T; Narod SA; Akbari MR
    Clin Genet; 2015 Oct; 88(4):366-70. PubMed ID: 25330149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Late-Onset Breast Cancer in Genetically Predisposed Women.
    Boddicker NJ; Hu C; Weitzel JN; Kraft P; Nathanson KL; Goldgar DE; Na J; Huang H; Gnanaolivu RD; Larson N; Yussuf A; Yao S; Vachon CM; Trentham-Dietz A; Teras L; Taylor JA; Scott CE; Sandler DP; Pesaran T; Patel AV; Palmer JR; Ong IM; Olson JE; O'Brien K; Neuhausen S; Martinez E; Ma H; Lindstrom S; Le Marchand L; Kooperberg C; Karam R; Hunter DJ; Hodge JM; Haiman C; Gaudet MM; Gao C; LaDuca H; Lacey JV; Dolinsky JS; Chao E; Carter BD; Burnside ES; Bertrand KA; Bernstein L; Auer PW; Ambrosone C; Yadav S; Hart SN; Polley EC; Domchek SM; Couch FJ
    J Clin Oncol; 2021 Nov; 39(31):3430-3440. PubMed ID: 34292776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
    Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
    JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of a next generation sequencing assay for BRCA1, BRCA2, CHEK2 and PALB2 genetic testing.
    Sim WC; Lee CY; Richards R; Bettens K; Mottier V; Goh LL
    Exp Mol Pathol; 2020 Oct; 116():104483. PubMed ID: 32531196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.